Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer

Gastrointestinal Cancer

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Eur J Cancer

Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V

doi: 10.1016/j.ejca.2025.116105

Gastrointestinal Cancer

Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment

Eur J Cancer

Debiais M, Tarabay A, Blanchet-Deverly S, Camilleri GM, Megherbi A, Diebakate L, Collin M, Hollebecque A, Smolenschi C, Valéry M, Pudlarz T, Fuerea AC, Boige V, Ducreux M, Boilève A

doi: 10.1016/j.ejca.2025.116160

Inflammatory Bowel Disease

Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data

BMC Gastroenterol

Dignass A, Teich N, Kaiser S, Sünwoldt J, Dünweber C, Weinhold I, Borchert J, Kudernatsch R

doi: 10.1186/s12876-025-04022-7

Gastrointestinal Cancer

Investigating the causal effect of potential therapeutic agents for colorectal cancer prevention: a Mendelian randomization analysis

Cancer Epidemiol Biomarkers Prev

Fryer E, Bishop DT, Campbell PT, Chan AT, Le Marchand L, Li CI, Moreno V, Gunter MJ, Phipps AI, Grant RC, Schmit SL, Martin RM, Yarmolinsky J, Haycock P

doi: 10.1158/1055-9965.EPI-25-0875

Further Publications

Heterogeneity of treatment preferences in the absence of guideline recommendations - a case vignette study in colorectal cancer tumor boards in Germany, Austria and Switzerland

BMC Gastroenterol

Soff J, Benz SR, Kowalski C, Hansinger J, Gerken M, Maier D, Kim-Wanner SZ, Witzmann J, Reinacher-Schick A, Pox CP, Kleihues-van Tol K, Franke B, Schoffer O, Schmitt J, Klinkhammer-Schalke M, Völkel V, onkoFDZ Study Group

doi: 10.1186/s12876-025-04183-5

Gastrointestinal Cancer

Evaluation of the efficacy of probiotics in the chemoradiotherapy of colorectal cancer: a meta-analysis of Randomized Controlled Trials

BMC Gastroenterol

Yang R, Liu W, Cai S, Feng X, Chen Y, Cheng X, Ma J, Ma W, Tian Z, Yang W

doi: 10.1186/s12876-025-03914-y

Gastrointestinal Cancer

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Adv Ther

Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH

doi: 10.1007/s12325-025-03133-7

Gastrointestinal Cancer

Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis

Eur J Cancer

Bregni G, Leurquin B, Giasafaki P, Takemura N, Kokudo N, Hasegawa K, Matsuyama Y, Nishioka Y, Aparicio T, Guimbaud R, Malicot KL, Tu D, O'Callaghan C, Lutz MP, Fontana E, Moehler M, Mauer ME, Sclafani F

doi: 10.1016/j.ejca.2025.116092

Gastrointestinal Cancer

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons

Adv Ther

Ajani JA, Wang K, Nikolaidis GF, Coaquira Castro J, Augusto Novis de Figueiredo M, Sun JM, Soulanis K, Tasoulas A, Zhan L

doi: 10.1007/s12325-025-03410-5

Related content

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment

Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data

Investigating the causal effect of potential therapeutic agents for colorectal cancer prevention: a Mendelian randomization analysis

Heterogeneity of treatment preferences in the absence of guideline recommendations - a case vignette study in colorectal cancer tumor boards in Germany, Austria and Switzerland

Evaluation of the efficacy of probiotics in the chemoradiotherapy of colorectal cancer: a meta-analysis of Randomized Controlled Trials

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons